Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV Type 1 Infected Patients attending Clinics in Kinshasa, Democratic Republic of Congo

Kamangu, Erick Ntambwe

doi:10.16966/2380-5536.101

Cited by 10 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data do not corroborate those of Kamangu NE and al. in his study carried out in 2015 in Kinshasa in the Democratic Republic of Congo (DRC) [22] . After sequencing the Protease on 130 samples and the Transcriptase Reverse on 145 samples, in a study carried out on 153 PLHIV, he had found that subtype A was the most represented (22.87%) followed by the Recombinant Circulating Form CRF02_AG (11.11%).…”

Section: Discussionmentioning

confidence: 99%

Correlation between sequencing results on plasma and on dried blood Spot for the determination of non-B subtypes of HIV Type 1 in Nrsquo;djamena, chad: About 30 samples

Adawaye,

Kamangu,

Fouda

et al. 2019

Int. J. HIV AIDS Res.

View full text Add to dashboard Cite

Context: Easily applicable, the Dried Blood Spot (DBS) makes it possible to collect blood drawn from a tube or by pricking in the heel or finger, both in town and in decentralized regions. They allow samples to be stored at room temperature or cold, in airtight bags to prevent humidity. Objective: The aim of this work was to determine the correlation between the results of sequencing on liquid plasma and on DBS in N'Djamena, Chad. Methods: The blood of 50 patients living with HIV was drawn on a tube with EDTA and 30 of them were randomly put on Whatman ® 903 type DBS. The drying was done overnight at room temperature. Storage was done at -20 ° C. Viral RNA extraction was performed with the QiAamp Viral RNA mini kit. The viral load on DBS and on plasma was carried out at LRS CHU-ULg. The determination of the variants was obtained after analysis on the Stanford University/HIV Drug Resistance Database site. The interpretation of the resistances is made in accordance with the algorithm of the ANRS AC11. Results: An amplification rate of 80% is obtained on the DBS with a detection limit of the blotter is 3.33 log 10 copies of RNA/ml. The subtypes obtained on the Protease sequences, which is the least changing region of the virus were retained. CRF02_AG is the most represented both on DBS with 29.17% and on plasma with 30.23%. Sequencing on DBS showed the presence of the K subtype (12.5%) at the level of the Reverse Transcriptase while it is absent in the plasma after sequencing. Conclusion: An amplification success rate of 80% compared to plasma was observed in this study. However, DBS can be useful for the evaluation of antiretroviral therapy for non-B subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between sequencing results on plasma and on dried blood Spot for the determination of non-B subtypes of HIV Type 1 in Nrsquo;djamena, chad: About 30 samples

Adawaye,

Kamangu,

Fouda

et al. 2019

Int. J. HIV AIDS Res.

View full text Add to dashboard Cite

show abstract

“…These EWIs include: 1) the practice of prescribing ART, 2) patients lost of sight during the first 12 months of ART, 3) patients on an appropriate first-line regimen for 12 months, 4) receiving ARVs on time, 5) respect of ART appointments, 6) constancy of ARV delivery, 7) observation of ART by patients, and 8) suppression of Viral Load (VL) 12 months after initiating ART. In Kinshasa, the HIVDR rate among patients initiating ART was around 8% in 2014 [3] [4]. Thus the objective of this study was to evaluate the quality of the prevention of the occurrence of treatment failures and the HIVDR compared to EWI according to WHO some Ambulatory Treatment Centers (ATCs) of Kinshasa.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Okonda¹,

Bulanda²,

Kabasele³

et al. 2019

OALib

View full text Add to dashboard Cite

Background: The Early Warning Indicators (EWI) of Human Immunodeficiency Virus (HIV) Drug Resistance measure factors found at the site level and known to be associated with the proper functioning of the program and the prevention of the emergence of R-ARV. The fact strengthening certain aspects of implementation of the program at the sites can help minimize the occurring of HIV Drug Resistance that can be prevented to improve the long-term effectiveness and sustainability of the treatment. Objective: The objective of this study was to assess the quality of the prevention of resistance of HIV Drug compared to EWI set by the World Health Organization (WHO) in the different Ambulatory Treatment Centers (ACT) in the city of Kinshasa. Methods: The present work was a retrospective survey conducted in 2015 in 7 ACTs in the 4 districts of Kinshasa in order to evaluate the EWI. Results: Seven (7) ATCs and 157 patient records were selected based on different inclusion criteria. The maintenance of first-line Antiretroviral Treatment (ART) at 12 months and the consistent delivery of ARVs were the two EWI that were respected, evaluation at 100%, for 6 ACTs. Conclusion: The caregivers and HIV-infected patients should be trained on the EWI and their monitoring to prevent the occurrence of treatment failures and that of HIV drug resistance in Kinshasa.

show abstract

Current and historic HIV-1 molecular epidemiology in paediatric and adult population from Kinshasa in the Democratic Republic of Congo

Rubio-Garrido

González-Alba

Reina

et al. 2020

Sci Rep

View full text Add to dashboard Cite

HIV-1 diversity may impact monitoring and vaccine development. We describe the most recent data of HIV-1 variants and their temporal trends in the Democratic Republic of Congo (DRC) from 1976 to 2018 and in Kinshasa from 1983–2018. HIV-1 pol sequencing from dried blood collected in Kinshasa during 2016–2018 was done in 340 HIV-infected children/adolescents/adults to identify HIV-1 variants by phylogenetic reconstructions. Recombination events and transmission clusters were also analyzed. Variant distribution and genetic diversity were compared to historical available pol sequences from the DRC in Los Alamos Database (LANL). We characterized 165 HIV-1 pol variants circulating in Kinshasa (2016–2018) and compared them with 2641 LANL sequences from the DRC (1976–2012) and Kinshasa (1983–2008). During 2016–2018 the main subtypes were A (26.7%), G (9.7%) and C (7.3%). Recombinants accounted for a third of infections (12.7%/23.6% Circulant/Unique Recombinant Forms). We identified the first CRF47_BF reported in Africa and four transmission clusters. A significant increase of subtype A and sub-subtype F1 and a significant reduction of sub-subtype A1 and subtype D were observed in Kinshasa during 2016–2018 compared to variants circulating in the city from 1983 to 2008. We provide unique and updated information related to HIV-1 variants currently circulating in Kinshasa, reporting the temporal trends of subtypes/CRF/URF during 43 years in the DRC, and providing the most extensive data on children/adolescents.

show abstract

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV Type 1 Infected Patients attending Clinics in Kinshasa, Democratic Republic of Congo

Cited by 10 publications

References 29 publications

Correlation between sequencing results on plasma and on dried blood Spot for the determination of non-B subtypes of HIV Type 1 in Nrsquo;djamena, chad: About 30 samples

Correlation between sequencing results on plasma and on dried blood Spot for the determination of non-B subtypes of HIV Type 1 in Nrsquo;djamena, chad: About 30 samples

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Current and historic HIV-1 molecular epidemiology in paediatric and adult population from Kinshasa in the Democratic Republic of Congo

Contact Info

Product

Resources

About